SCHEMBL2477650

SCHEMBL2477650

NC(=O)c1cnc(Cl)cc1NCc1ccc(F)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 8/20 0.52
AURKA O14965 3/20 0.52
VNN1 O95497 2/20 0.48
AKT1 P31749 2/20 0.47
JAK3 P52333 4/20 0.46
IRAK4 Q9NWZ3 2/20 0.46
JAK2 O60674 2/20 0.46
JAK1 P23458 2/20 0.46
TYK2 P29597 2/20 0.46
MAPK8 P45983 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
PREP P48147 1/20 0.41
CDC7 O00311 1/20 0.41
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
PIM1 P11309 1/20 0.41
CDK2 P24941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2482122 0.87 RPS6KB1 (0.52) RPS6KB1AURKAVNN1AKT1JAK3
SCHEMBL2479527 0.87 JAK3 (0.53) RPS6KB1VNN1AKT1JAK3IRAK4
SCHEMBL2483572 0.85 RPS6KB1 (0.54) RPS6KB1AURKAAKT1JAK3IRAK4
SCHEMBL2475770 0.84 CDC7 (0.58) RPS6KB1AURKAAKT1JAK3IRAK4
SCHEMBL2482471 0.84 RPS6KB1 (0.60) RPS6KB1AURKAVNN1AKT1JAK3
SCHEMBL2480070 0.83 RPS6KB1 (0.48) RPS6KB1AURKAAKT1JAK3IRAK4
SCHEMBL12280471 0.83 JAK3 (0.43) RPS6KB1AURKAVNN1JAK3IRAK4
SCHEMBL12456545 0.83 JAK3 (0.52) RPS6KB1AURKAAKT1JAK3IRAK4
SCHEMBL12280201 0.82 JAK3 (0.48) JAK3IRAK4JAK2JAK1TYK2
SCHEMBL2479053 0.82 KDM4E (0.51) VNN1JAK3IRAK4JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
CN-102227409-A Pyridine-3-carboxyamide derivative KOWA CO 2011-10-26 CN disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA RPS6KB1 3316/4885AURKA 971/4885VNN1 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.